cgp 39551 has been researched along with valproic acid in 1 studies
| Studies (cgp 39551) | Trials (cgp 39551) | Recent Studies (post-2010) (cgp 39551) | Studies (valproic acid) | Trials (valproic acid) | Recent Studies (post-2010) (valproic acid) |
|---|---|---|---|---|---|
| 75 | 0 | 4 | 14,155 | 1,256 | 5,108 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Czechowska, G; Czuczwar, SJ; Dziki, M; Kleinrok, Z; Pietrasiewicz, T; Turski, WA | 1 |
1 other study(ies) available for cgp 39551 and valproic acid
| Article | Year |
|---|---|
Competitive antagonists of NMDA receptors, CGP 37849 and CGP 39551, enhance the anticonvulsant activity of valproate against electroconvulsions in mice.
Topics: 2-Amino-5-phosphonovalerate; Animals; Anticonvulsants; Behavior, Animal; Dose-Response Relationship, Drug; Drug Synergism; Electroshock; Male; Mice; Receptors, N-Methyl-D-Aspartate; Seizures; Valproic Acid | 1993 |